Тетравалентная вакцина против денге: анализ затрат и приоритетных групп

Dr. Luis Cousirat, director of the Expanded Program of Immunization (EPI), reported on the follow-up to the meeting of WHO experts, who last week gave their approval to the tetravalent vaccine against dengue, a live attenuated virus vaccine, whose technology is recognized by the Ministry of Health, as it was used in other biologicals against measles and yellow fever. The director explained that this tetravalent vaccine has the particularity of being developed on dengue serotype two, which makes it very effective, especially against serotypes one and two, mainly in people who have already had the disease (seropositive patients). Asked if this vaccine protects against den 4, which is feared to unleash an epidemic of hemorrhagic dengue this summer, he answered that it does, but to a lesser extent.this vaccine is available in the private sector in Brazil and Argentina, but not in the public sector, where the large-scale production of this biological product is pending. "We are forming a working group to see pending aspects such as costs, resources, age groups to include, define the target population", confirmed the director in an interview with radio Universo 970 AM.